499 assets in Hepatocellular Carcinoma

Therapeutic assets addressing Hepatocellular Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
IMA970A Hepatocellular Carcinoma	National Cancer Institute, Naples	P1/2	CCC (49)
Immunoglobulin G1 [De-448-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mouse Monoclonal C225 ?1-Chain) Fusion Protein With Peptide Linker (Ggggs)2 Fusion Protein With Immunoglobulin Anti-(Human Epidermal Growth Factor Receptor Her3) (Human Clone Her3.H3 Single-Chain Variable Fragment Vh-(Ggggs)3-Vl), Complex With Human-Mouse Monoclonal C225 ?-Chain, Dimer, 214??,214???,222,222?,228,228?,231,231?-Octakis(Thioether) With (2S)-N-(Carboxymethyl)-2-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-?-Alanylglycylglycyl-L-Phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-1-Methyl-2-Oxoethoxy]Methyl]Glycinamide Hepatocellular Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (49)
Irpagratinib Hepatocellular Carcinoma	Asan Medical Center	P2	CCC (49)
Ligufalimab Hepatocellular Carcinoma	University of Texas Southwestern Medical Center	P2	CCC (49)
Lparomlimab Hepatocellular Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (49)
NKT2152 Hepatocellular Carcinoma	NiKang Therapeutics, Inc.	P2	CCC (49)
Pimurutamab Hepatocellular Carcinoma	Shanghai Henlius Biotech	P2	CCC (49)
Sonidegib Hepatocellular Carcinoma	University of Florida	P2	CCC (49)
Spartalizumab Hepatocellular Carcinoma	SOLTI Breast Cancer Research Group	P2	CCC (49)
Tcr-T Cells Hepatocellular Carcinoma	Lion TCR Pte. Ltd.	P1/2	CCC (49)
Triadeno Vaccine Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (49)
Tuvonralimab Hepatocellular Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (49)
Vancomycin Hepatocellular Carcinoma	Michael Dill	P2	CCC (49)
YH 001 Hepatocellular Carcinoma	Eucure (Beijing) Biopharma Co., Ltd	P2	CCC (49)
zg005 Hepatocellular Carcinoma	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P2	CCC (49)
e7386 Hepatocellular Carcinoma	Eisai Inc.	P1/2	CCC (48)
FAPI74 Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (48)
Futibatinib Hepatocellular Carcinoma	Mayo Clinic	P2	CCC (48)
H-Gamma1 Heavy Chain Homo Sapiens (1-447) [Vh (Homo Sapiens Ighv4-5901 (99.0%) -(Ighd) -Ighj302 (93.3%) T125>I (114), Cdr-Imgt [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo Sapiens Ighg101, G1M17,1 Ch1 K120, Ch3 D12, L14, 9-G1V21 Ch2 Y15.1, T16, E18 (Ch1 K120 (214) (118-215), Hinge 1-15 (216-230), Ch2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), Ch3 D12 (356), L14 (358) (341-445), Chs (446-447)) (118-447)], (220-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv3-1101 (96.8%) -Igkj401 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc01 (100%) Km3 A45.1, V101 (Ckappa A45.1 (153'), V101 (191')) (108'-214')]; Dimer (226-226'':229-229'')-Bisdisulfide, Produced In A Cell Line Derived From Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa Hepatocellular Carcinoma	Kineta Inc.	P1/2	CCC (48)
Idarubicin Hydrochloride For Hepatocellular Carcinoma	Zhongda Hospital	P2/3	CCC (48)
Immunoglobulin G1, Anti-(Human Interleukin 27) (Human Monoclonal Srf388 ?1-Chain), Disulfide With Human Monoclonal Srf388 ?-Chain, Dimer Hepatocellular Carcinoma	Coherus Oncology, Inc.	P2	CCC (48)
kd6001 Hepatocellular Carcinoma	Shanghai Kanda Biotechnology Co., Ltd.	P1/2	CCC (48)
Memantine Hepatocellular Carcinoma	Inova Health Care Services	P2/3	CCC (48)
Novaferon Hepatocellular Carcinoma	M.D. Anderson Cancer Center	P1/2	CCC (48)
PCV 13 Hepatocellular Carcinoma	Mayo Clinic	P1/2	CCC (48)
Pembrolizumab/Vibostolimab Coformulation Hepatocellular Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (48)
Renvatinib Hepatocellular Carcinoma	First Affiliated Hospital of Guangxi Medical University	P1/2	CCC (48)
Rulonilimab Hepatocellular Carcinoma	Shandong New Time Pharmaceutical Co., LTD	P2/3	CCC (48)
Sargramostim Hepatocellular Carcinoma	Mayo Clinic	P1/2	CCC (48)
Tobemstomig Hepatocellular Carcinoma	Hoffmann-La Roche	P1/2	CCC (48)
b1962 Hepatocellular Carcinoma	Tasly Biopharmaceuticals Co., Ltd.	P2	CC (47)
bb102 Hepatocellular Carcinoma	Broadenbio Ltd., Co.	P2	CC (47)
bc3402 Hepatocellular Carcinoma	Case Comprehensive Cancer Center	P1/2	CC (47)
Bumetanide Hepatocellular Carcinoma	Memorial Sloan Kettering Cancer Center	P1/2	CC (47)
Copanlisib Hepatocellular Carcinoma	Bayer	P2	CC (47)
Fostrox Hepatocellular Carcinoma	CHA University	P2	CC (47)
mdx2001 Hepatocellular Carcinoma	ModeX Therapeutics, An OPKO Health Company	P1/2	CC (47)
Ondansetron Hepatocellular Carcinoma	First Affiliated Hospital of Wenzhou Medical University	P2	CC (47)
q702 Hepatocellular Carcinoma	Qurient Co., Ltd.	P1/2	CC (47)
Tak-500 Hepatocellular Carcinoma	Takeda	P1/2	CC (47)
Tinengotinib Hepatocellular Carcinoma	Akeso	P2	CC (47)
Lorigerlimab Hepatocellular Carcinoma	MacroGenics	P1	CC (46)
1.0% ip-001 for Hepatocellular Carcinoma	Robert C. Martin	P2	CC (45)
abx196 Hepatocellular Carcinoma	Abivax S.A.	P1/2	CC (45)
Adbelimumab Hepatocellular Carcinoma	Fujian Cancer Hospital	P2	CC (45)
Atilizumab Hepatocellular Carcinoma	Abbisko Therapeutics Co, Ltd	P2	CC (45)
Atirizumab Hepatocellular Carcinoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	CC (45)
Autologous Dendritic Cell/Tumor Antigen, Adcta Hepatocellular Carcinoma	Chang Gung Memorial Hospital	P2	CC (45)
Avatrombopag Hepatocellular Carcinoma	Second Affiliated Hospital of Guangzhou Medical University	P2	CC (45)
Bifidobacterium Bifidum Hepatocellular Carcinoma	Sun Yat-sen University	P1/2	CC (45)

Showing 201 to 250 of 499 assets

PreviousPage 5 of 10Next